Thermo Fisher and Roche enjoy COVID-19 diagnostic tailwinds, but warn of routine testing declines

Thermo Fisher Scientific is predicting COVID-19 testing could create a $750 million tailwind in the second quarter. But in first quarter results posted Wednesday, the company also said that benefit is likely to be more than offset by disruptions from COVID-19, which could cause overall sales to fall 15% on an organic basis.